Drug Trial News

RSS

Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death

A pooled analysis of three large trials failed to demonstrate significant reductions in cardiovascular death with finerenone, but significantly lower all-cause mortality, cardiovascular events and kidney outcomes were observed, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

2 Sep 2024

$Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction$

Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial led by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system.

2 Sep 2024

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

2 Sep 2024

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

Edoxaban monotherapy reduced net adverse clinical events compared with edoxaban plus a single antiplatelet agent, when used as long-term antithrombotic therapy, in patients with high-risk atrial fibrillation (AF) and stable coronary artery disease (CAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

Asundexian 50 mg daily was inferior to apixaban for stroke and systemic embolism prevention in high-risk patients with atrial fibrillation (AF), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI), a Mount Sinai-led global team of researchers has shown.

1 Sep 2024

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

New research shows that a treatment plan based on novel combination of low doses of three anti-hypertensive drugs in a single pill - known as GMRx2 - was superior to a high-quality standard care treatment plan at lowering blood pressure in patients with uncontrolled hypertension.

1 Sep 2024

QUADRO trial demonstrates superior blood pressure control with four-in-one medication

A single-pill combination of four blood-pressure (BP)-lowering medications was significantly more effective than a combination of three medications, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

1 Sep 2024

Vutrisiran shows potential to become the new standard of care for rare heart disease

Vutrisiran significantly improved mortality, cardiovascular events and markers of disease progression in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.

30 Aug 2024

Ingenza announces partnership with Cellugy to investigate the potential of biofabricated cellulose

Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with Cellugy to accelerate the development of its innovative platform for producing biofabricated cellulose. This technology will provide a sustainable alternative to fossil-based petrochemicals in various industrial applications, starting with personal care. The new project will ultimately accelerate the understanding and optimization of bacterial cellulose production.

From Ingenza Ltd 30 Aug 2024

Ishani Malhotra named ‘woman entrepreneur of the year’ by cancer research horizons

Cancer Research Horizons, the innovation arm of Cancer Research UK, announced the winners of its second Innovation & Entrepreneurship Awards at it’s gala dinner on the 20th of March in London.These awards celebrate the UK’s most innovative and enterprising efforts in oncology highlighting those individuals in the industry working hard to translate discoveries into benefits for cancer patients.

From Carcinotech 30 Aug 2024

Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development

Advances in tissue engineering and 3D bioprinting have revolutionized the development of physiologically relevant 3D in vitro cancer models, offering a closer representation of the tumor microenvironment (TME) and enabling high-throughput drug screening.

From Carcinotech 30 Aug 2024

AmelHap: A honeybee haplotype map

Beebytes is very happy to have achieved its first publication, the development of a ‘HapMap’ for honey bees, in collaboration with the Roslin Institute, the University of the Basque Country in Spain, and the National Research Institute for Agriculture, Food and the Environment (INRAE) in France.

From Beebytes Analytics 30 Aug 2024

Probenecid shows promise for easing opioid withdrawal symptoms in new study

A deeper understanding of the communication inside the body when someone is going through opioid withdrawal has led to a new clinical trial at the University of Calgary.

29 Aug 2024

New method emulates clinical trial to compare blood thinners for atrial fibrillation

Researchers used real-world clinical data to attempt to emulate a randomized controlled trial testing the effectiveness of two blood thinners, apixaban and warfarin, to prevent stroke in patients with non-valvular atrial fibrillation.

29 Aug 2024

Study shows benefits of taking misoprostol at home during medical abortions after 12 weeks

Pregnant people who took the first dose of misoprostol (a pill given as part of the procedure for medical abortions) at home had a 71% chance of completing their care in hospital within 9 hours with no overnight stay when having an abortion after 12 weeks of pregnancy, compared to 46% of those who took the first dose of misoprostol at hospital, finds a randomized controlled trial published in The Lancet.

29 Aug 2024

TCT 2024 to feature latest advances in interventional cardiovascular medicine

The Cardiovascular Research Foundation is pleased to announce the late-breaking clinical trials and science to be featured at TCT 2024.

28 Aug 2024

Investigational drug reduces hot flashes associated with menopause

The investigational drug elinzanetant significantly reduces the frequency and severity of hot flashes associated with menopause while improving women's quality of life, new UVA Health research published in the prestigious Journal of the American Medical Association shows.

22 Aug 2024

Belzutifan shows promise in treating advanced renal cell carcinoma

The LITESPARK-005 phase 3 clinical enrolled 746 patients with metastatic clear cell renal cell carcinoma (ccRCC) who had progressed after treatment with both an immune checkpoint inhibitor (ICI) and an anti-angiogenic therapy.

21 Aug 2024

Tecovirimat shows no significant impact on mpox lesion duration in DRC study

The antiviral drug tecovirimat did not reduce the duration of mpox lesions among children and adults with clade I mpox in the Democratic Republic of the Congo (DRC), based on an initial analysis of data from a randomized, placebo-controlled trial.

16 Aug 2024

Drug Trial News

Pooled analysis shows finerenone reduces all-cause mortality but not cardiovascular death

Finerenone shows promise for heart failure with mildly reduced or preserved ejection fraction

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Edoxaban monotherapy superior to dual therapy in patients with high-risk AF and stable CAD

OCEANIC-AF trial reveals inferiority of asundexian to apixaban for stroke prevention

New study confirms safety of SGLT2 inhibitors after acute myocardial infarction

Triple-pill combination GMRx2 outperforms standard care in lowering blood pressure

QUADRO trial demonstrates superior blood pressure control with four-in-one medication

Vutrisiran shows potential to become the new standard of care for rare heart disease

Ingenza announces partnership with Cellugy to investigate the potential of biofabricated cellulose

Ishani Malhotra named ‘woman entrepreneur of the year’ by cancer research horizons

Carcinotech publishes research on patient-derived 3D-printed tumors as a breakthrough tool for drug development

AmelHap: A honeybee haplotype map

Probenecid shows promise for easing opioid withdrawal symptoms in new study

New method emulates clinical trial to compare blood thinners for atrial fibrillation

Study shows benefits of taking misoprostol at home during medical abortions after 12 weeks

TCT 2024 to feature latest advances in interventional cardiovascular medicine

Investigational drug reduces hot flashes associated with menopause

Belzutifan shows promise in treating advanced renal cell carcinoma

Tecovirimat shows no significant impact on mpox lesion duration in DRC study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News